(CTN News) – Antibody-based therapies may combat influenza B, according to a recent study.
According to Dr Hillary Vanderven of James Cook University, antibody-based treatments for respiratory viruses are becoming increasinglydue to their ability to treat severe respiratory infections in high-risk populations.
According to Dr Vanderven, a lecturerand infectious diseases at the University of Copenhagen, antibodies are by the immune system to attack specific molecules on pathogens.
It is true that antibody-based therapeutics are safe, but clinical trials have generally shown a minimal or no effect on influenza A, and at this time there is no FDA-approved antibody-based treatment for humanB.
A recent clinical trial used hyperimmune intravenous immunoglobulin (Flu-IVIG) – purified from donors who had either been vaccinated against– which contained antibodies to combat flu infections – which was used in the study.
“This new therapy has been tested on 308 patients hospitalized with severe influenza A or
B,” said Dr Vanderven, the study’s lead author.
Treatment withfor patients with influenza B, but did not show any benefit for patients with influenza A.
According to thisstudy, the researchers wanted to find out why therapy was only effective for influenza B by measuring different types of study why it was only effective.
that certain types of antibodies to influenza, infected cells, could assist in the recovery of a severe case of influenza B, but not of influenza A.
It has become increasingly urgent to develop antibody-based treatments for respiratory virusesthe increasing prevalence of these viruses.
As a result of influenza, COVID-19, andin the community, there is need for an expanded arsenal of antiviral therapies to fight severe respiratory infections.
The extensive analysis of serum antibodies has provided us with valuable insights into the mechanisms and antibody characteristics that underpin the development of effective humoral immunity to influenza viruses. By using this knowledge, we will be able to develop new and improvedtherapies.”